Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Maintenance in Extensive Stage SCLC
NCT02359019Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Feb 2015
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in small cell lung cancer (SCLC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Feb 2015; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02359019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359019.